ABN/ARSN

15 088 417 403

Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Name of entity

Sigma Pharmaceuticals Limited

1	ormation about buy-back Type of buy-back	On-market buy-back			
2	Date Appendix 3C was given to ASX	13 September 2012			
Total of all shares/units bought back, or in relation to which acceptances have been received, before, and on, previous day Before previous day Previous day					
	e been received, before, and	on, previous day	-		
	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	on, previous day	-		

		Before p	revious	s day	Previous day
5	If buy-back is an on-market buy-back	Highest \$0.8525	price	paid:	Highest price paid: \$0.5800
		Lowest	price	noide	Lowest price paid: \$0.5650
		\$0.5600	price	paid:	Highest price allowed under rule 7.33: \$0.5964

How many shares/units may still be bought back?

6	If the company/trust has disclosed	55,179,250
	an intention to buy back a	
	maximum number of shares/units –	
	the remaining number of	
	shares/units to be bought back	

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here: Date: 8 November 2013

(Director/Company secretary)

Print name: SUE MORGAN

== == == == ==